Quris-AI and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) signed an agreement during Abu Dhabi Sustainability Week (ADSW) to develop a world-class Bio-AI center in Abu Dhabi. The state-of-the-art facility will support the development of personalized medications, tailored specifically to the diverse populations of the MENA region.
The collaboration will establish a center of excellence in Bio-AI in Abu Dhabi, which will accelerate the development of safer, and more highly personalized medications. MBZUAI provides expertise in the development of predictive AI models, while incentivizing sought-after AI graduates to stay in the UAE as they begin their careers.
With this collaboration Quris, which has operations in Boston and Tel-Aviv, is now establishing its subsidiary, Quris-UAE in Abu-Dhabi.
We are delighted to be collaborating with Mohamed bin Zayed University of Artificial Intelligence in Abu Dhabi, given its strong commitment to advancing AI and significant opportunities for synergy,” said Isaac Bentwich M.D., founder and CEO of Quris. “We salute the vision of H.H. Sheikh Mohamed bin Zayed Al Nahyan, championing the UAE to become a center of excellence in AI as a strong pillar of the economy, and we are honored to contribute to realizing this vision.”
“One compelling aspect of my discussions with Professor Ciechanover and the Quris team have been about solving UAE-specific health problems faster and more cost-effectively,” said Professor Eric Xing, MBZUAI President and University Professor, and co-principal investigator in the Quris-MBZUAI collaboration. “The organelle systems being developed at Quris are a revolutionary platform for high-throughput drug testing, which can be best served by a similarly high-throughput drug design pipeline using AI. Our unique computational biology and machine learning capacities at MBZUAI will enhance Quris’ efforts to accelerate the development of new personalized and potentially life-saving medicines.”
As part of the collaboration, MBZUAI Deputy Department Chair and Associate Professor of Machine Learning Kun Zhang will drive a project titled: Disrupting Personalized Medicine using Patient-on-a-Chip and Causal Discovery. The project, which will draw on both organization’s resources and personnel, will accelerate discovery of personal, actionable causal effects on drug pharmacokinetics; genetic parameters with causal effect on drug metabolism; organ functional parameters relating to drug metabolism (e.g., liver/kidney/heart functional tests/assays); and ethnic-specific parameters affecting drug metabolism and safety. Additionally, the research will also support development of personalized (patient specific) drug administration protocol, as well as patient-on-a-chip method for causal discovery of patient-specific treatments.